Treatment costs for advanced prostate cancer using LHRH agonists: A solid biodegradable leuprorelin implant versus other formulations - Abstract

Aim: To compare treatment costs with alternative luteinizing hormone-releasing hormone agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings.

Patients & Methods: A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly prescribed luteinizing hormone-releasing hormone agonist preparations. Differentiated annual costs for 1- and 3-monthly formulations were calculated for France, Germany, Italy, Spain, the UK (EU5) and Sweden, and compared with the leuprorelin solid implant.

Results: Compared with alternative formulations, leuprorelin solid implants had potential annual cost savings/1000 patients of €562,000 (EU5) and €813,000 (Sweden) (1-month formulations) and €510,000 (EU5) and €365,000 (Sweden) (3-month formulations).

Conclusion: The leuprorelin solid implant was associated with potential cost savings compared with the most commonly used luteinizing hormone-releasing hormone agonist preparations.

Written by:
Merseburger AS, Björk T, Whitehouse J, Meani D.   Are you the author?
Department of Urology & Urologic Oncology, Hannover Medical School, Hannover, Germany.

Reference: J Comp Eff Res. 2014 Dec 18:1-7.

PubMed Abstract
PMID: 25521079 Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.